testosterone
PrintTrade Name(s): Depo-testosterone; Jatenzo; Kyzatrex; Natesto; Testopel; Tlando; Xyosted; Fortesta; Testim; Testosterone; Vogelxo | |
Group 3: Reproductive Hazard | AHFS Class: Androgens |
Action | Gloves | Gown | Eye/Face | Mask | CSTD | |
Dispensing prepackaged formulations |
| |||||
Preparing an Injectable Dose | If risk of spill or splash | If risk of inhalation | If dosage form allows |
| ||
Activity | Gloves | Gown | Eye/Face | Mask | Notes/Instructions |
All prepackaged formulations |
| ||||
Mixing | If risk of spill or splash | If risk of inhalation |
|
Formulation | Gloves | Gown | Eye/Face | Mask | CSTD |
Prepared injectable (vial, syringe, IV solution*, irrigation**) | or Recommended if pregnant, breast feeding, or trying to conceive | If splash possible or recommended if pregnant, breast feeding, or trying to conceive | If splash possible or recommended if pregnant, breast feeding, or trying to conceive | Recommended if pregnant, breast feeding, or trying to conceive | If dosage form allows |
Manufacturer packaged pre-filled syringe or injector | or Recommended if pregnant, breast feeding, or trying to conceive | if provided in kit, or if dosage form allows |
* Intravenous tubing already attached and primed.
** Bladder, HIPEC, limb perfusion, etc.
Reference: NIOSH 2016, USP <800>
Activity | Gloves | Gown | Eye/Face | Mask |
Administration | If risk of spill or splash | If risk of inhalation |
Reference: NIOSH 2016, USP <800>
Type of Instance | Gloves | Gown | Mask | Eye/Face | Notes/Instructions |
Receiving undamaged HD shipping container |
| ||||
Receiving damaged HD shipping container | If container must be opened | If container must be opened | If container must be opened |
| |
Spill Cleanup | Large volume | Large volume |
|
Reference: USP <800>
Hazardous Pharmaceutical | Trace Chemo | Biohazardous and Sharps |
1. Non-returnable hazardous, chemo and EPA regulated drugs. (Patient specific prescriptions, partially used blister packs, containers with more than 3% medication remaining) 2. Empty bottles or packaging of P-Listed drugs. (Warfarin, nicotine, epinephrine, nitroglycerin, physostigmine) 3. PPE with visible contamination from hazardous drug. | 1. Waste contaminated through contact with chemotherapeutic agents. (Empty vials, IV bags, syringes and tubing) 2. PPE worn while handling hazardous drugs with NO visible contamination. (Gowns, gloves and masks) 3. Used CSTD devices. | 1. All sharps capable of cutting or piercing the skin. (Needles/syringes, broken ampules, lancets) 2. Items contaminated with blood or other potentially infectious materials. (Tubing, bags or dressings containing blood, contaminated waste from isolation patients) |
Dosage Form | Ship to Institution or Pharmacy | Ship to Locations Outside of ODOC |
Tablets and Capsules |
|
|
Liquid, Topical, and Transdermal |
|
|
PPE | Standards |
Shoe Covers |
|
Gowns |
|
Gloves |
|
Face Shields |
|
Goggles |
|
N95 Masks |
|
Removal and Disposal |
|
Reference: USP <800>
- Harmful if swallowed
- May cause cancer
- Suspected of causing cancer
- May damage fertility or the unborn child
- Suspected of damaging fertility or the unborn child
- May cause harm to breast-fed children
- Causes damage to organs through prolonged or repeated exposure
- Very toxic to aquatic life
- Very toxic to aquatic life with long lasting effects
Reference: PubChem
CSA SCH: C-III
Testosterone mediates its effects by activating androgen receptors directly or as DHT, or being converted to estradiol which acts as an endogenous lignad on estrogen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT displays an androgenic potency that is about 2.5 times higher than to that of free T. Upon formation, the T-receptor or DHT-receptor complex undergoes a structural change that allows translocation of the complex into the cell nucleus and direct binding to the specific nucleotide sequences of the chromosomal DNA as a transcription factor. These specific nucleotide sequences are also called hormone response elements (HREs) that, when activated, promote transcriptional activity of certain genes responsible for the androgen effects.
Reference: Drug Bank